



Dirección Nacional de Medicamentos

República de El Salvador, América Central



UNIDAD DE INSPECCIÓN Y FISCALIZACIÓN

COMUNICACIÓN DE ALERTA

Santa Tecla, 07 de Marzo de 2016

LA DIRECCIÓN NACIONAL DE MEDICAMENTOS (DNM) ALERTA SOBRE *PRODUCTO: NOVODALIN B17*

Nivel de alerta: 1
Nombre del producto: Novodalin B17
Presentación/Forma Farmacéutica: No se detalla
Número de registro sanitario: No posee
Laboratorio Fabricante: No se detalla
Lotes: No se detalla
Fecha de vencimiento: No se detalla
Entidad emisora de la Alerta: Health Canadá
País de Origen: Canadá
Fecha de emisión de la Alerta: 07 de Marzo de 2016

Descripción del problema encontrado: Supuestamente destinado al tratamiento del cáncer donde detalla: Debido al contenido etiquetado, su consumo podría representar riesgo de intoxicación con cianuro. De acuerdo a la investigación realizada por la DNM No se encontró registro sanitario alguno ni importaciones de los productos.

La DNM alerta a toda la población a abstenerse de adquirir y/o suministrar éste producto, en virtud de que su uso representa un riesgo para la salud de la persona que lo consuma. En razón de que los productos Novodalin B17 NO cumplen con los requerimientos de calidad que avale su seguridad, calidad y eficacia.

La DNM recomienda no adquirir este tipo de producto ya que puede generar un riesgo a la salud. Así mismo recuerda adquirir los medicamentos en lugares autorizados por la DNM. Cualquier duda puede recurrir a ésta Dirección llamando al teléfono gratuito 136.

Se informa que la DNM continuará las acciones de vigilancia, como el aseguramiento de productos, para evitar la venta de los mismos porque representan un riesgo a la población.

Medicamentos a tu alcance

Blv. Merliot y Av. Jayaque, Edif. DNM, Urb. Jardines del Volcán, Santa Tecla, La Libertad, El Salvador, América Central
PBX: (503) 2522-5000 / e-mail: info@medicamentos.gob.sv



Dirección Nacional de Medicamentos

República de El Salvador, América Central



UNIDAD DE INSPECCIÓN Y FISCALIZACIÓN

ANEXOS

7/3/2017 "Novodalín B17/amygdalín" being sold online poses serious risk to health - Recalls and safety alerts

Government of Canada / Gouvernement du Canada **Canada**

Recalls and safety alerts

Home > Recalls & alerts

Share Contrast Print

"Novodalín B17/amygdalín" being sold online poses serious risk to health

Report a Concern

Starting date: February 23, 2016
Posting date: February 23, 2016
Type of communication: Advisory
Subcategory: Natural health products
Source of recall: Health Canada
Issue: Important Safety Information, Unauthorized products
Audience: General Public
Identification number: RA-57260

- Issue
- Who is affected
- Background
- Public enquiries
- What you should do
- Report health or safety concerns
- What Health Canada is doing

Issue

Health Canada is advising Canadians who purchased Novodalín B17, an unauthorized natural health product claiming to treat cancer to stop using the product and contact their doctor for appropriate follow-up. No health products containing B17 or amygdalín have been authorized by Health Canada to treat cancer or any other condition. Health Canada does not permit cancer treatment claims for natural health products. Decisions on cancer treatment should be made with your doctor.

Novodalín B17 being sold online by cdnf.com also poses serious risks to health as it is labelled to contain apricot kernel extract. Apricot kernels may contain amygdalín, a compound derived from bitter apricot kernels that has the potential to release cyanide when ingested by humans. The concentration of amygdalín is unknown at this time, however, ingesting low to moderate amounts of cyanide may lead to serious adverse health consequences and high doses may be lethal.

Products affected

Novodalín B17.

What you should do

- Consult with your doctor if you have used this product and have health concerns.
- Read the product label to verify that health products have been authorized for sale by Health Canada have an eight-digit DIN, a DIN-HM or a NPN.
- Verify if products that have been authorized for sale by searching the [Drug Product Database](#) and the [Licensed Natural Health Product Database](#).
- Report any adverse events to [Health Canada](#).
- Report complaints about health products to Health Canada by calling toll-free to 1-800-267-9675, or complete an [online complaint form](#).

Who is affected

Consumers who have bought or used Novodalín B17.

Background

No drug products containing B17 or amygdalín have been approved by Health Canada.

Health Canada has previously communicated on the risk of buying [drugs](#), [natural health products](#) or [medical devices](#) online. The [healthycanadians](#) website also routinely informs consumers about unlicensed health products that have been found on the Canadian market.

Unlicensed products have not been reviewed by Health Canada for safety, quality or effectiveness. They may contain hidden ingredients not listed on the label, dangerous additives and/or contaminated ingredients. In addition, they may lack the active ingredients Canadians would expect them to contain to help maintain and improve their health. For all of these reasons, they could cause serious health effects.

Report health or safety concerns

- Call toll-free at 1-866-234-2345
- Visit MedEffect Canada's web page on [Adverse Reaction Reporting](#) for information on how to report online, by mail or by fax.

Stay connected with Health Canada and receive the latest advisories and product recalls using [social media](#) tools.

<http://healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2016/57260a-eng.php>



Dirección Nacional de Medicamentos

República de El Salvador, América Central



UNIDAD DE INSPECCIÓN Y FISCALIZACIÓN


7/3/2017 *Novodalín B17/amygdalín* being sold online poses serious risk to health - Recalls and safety alerts

Media enquiries
 Health Canada
 (613) 957-2983

Public enquiries
 (613) 957-2991
 1-866-225-0709

What Health Canada is doing
 Health Canada has requested the online seller to stop sale and will take further action and advise Canadians should additional risks be identified.

Images
 Select thumbnail to enlarge



Date modified: 2016-02-24

